INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
Public company

PLRXPLIANT THERAPEUTICS, INC.

CIK 0001746473

EDGAR filingsOpen in network
Disclosed transactions8
Buys / sells0 / 4
Max Insider Score27
Connections5with evidence

PLRX · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
CL
Cummings Keith LamontChief Financial Officer
PLRXPLIANT THERAPEUTICS, INC.
Grant or award
A—
400.0K sh
Jan 22, 2026Jan 26, 2026
traded Jan 22, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 5, 2026
  • ← Insider ofevidence
    Cummings Keith LamontChief Financial Officer · Jan 22, 2026
  • ← Insider ofevidence
    Cheung LilyChief Human Resource Officer · Jan 22, 2026
  • ← Insider ofevidence
    Coulie BernardDirector, President and CEO · Jan 22, 2026
5
KM
Kuo MinnieChief Operating Officer
PLRXPLIANT THERAPEUTICS, INC.
Grant or award
A
—
300.0K sh
Jan 22, 2026
Jan 26, 2026
traded Jan 22, 2026
+4d
SEC FORM 4

Evidence

5
CL
Cheung LilyChief Human Resource Officer
PLRXPLIANT THERAPEUTICS, INC.
Grant or award
A—
300.0K sh
Jan 22, 2026Jan 26, 2026
traded Jan 22, 2026
+4dSEC FORM 4

Evidence

5
CB
Coulie BernardDirector, President and CEO
PLRXPLIANT THERAPEUTICS, INC.
Grant or award
A—
1.23M sh
Jan 22, 2026Jan 26, 2026
traded Jan 22, 2026
+4dSEC FORM 4

Evidence

24
CL
Cummings Keith LamontChief Financial Officer
PLRXPLIANT THERAPEUTICS, INC.
Open-market sale · 10b5-1 plan
SELL$31K
24.0K sh
Jan 20, 2026Jan 22, 2026
traded Jan 20, 2026
+2dSEC FORM 4

Evidence

24
CL
Cheung LilyChief Human Resource Officer
PLRXPLIANT THERAPEUTICS, INC.
Open-market sale · 10b5-1 plan
SELL$9,644
7,534 sh
Jan 20, 2026Jan 22, 2026
traded Jan 20, 2026
+2dSEC FORM 4

Evidence

27
CB
Coulie BernardDirector, President and CEO
PLRXPLIANT THERAPEUTICS, INC.
Open-market sale · 10b5-1 plan
SELL$114K
89.4K sh
Jan 20, 2026Jan 22, 2026
traded Jan 20, 2026
+2dSEC FORM 4

Evidence

24
KM
Kuo MinnieChief Operating Officer
PLRXPLIANT THERAPEUTICS, INC.
Open-market sale · 10b5-1 plan
SELL$8,854
6,917 sh
Jan 20, 2026Jan 22, 2026
traded Jan 20, 2026
+2dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Kuo MinnieChief Operating Officer · Jan 22, 2026